Curis Inc (CRIS): Shareholders' Equity
$5.46M
As of 2025-12-31
$4.70M
As of 2026-06-30
-51.0%
3-year compound annual growth
-47.0%
5-year compound annual growth
-21.9%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.46M | n/m | 2026-03-24, Balance as of period end |
| 2024-12-31 | -$6.00M | n/m | 2026-03-24, Balance as of period end |
| 2023-12-31 | $19.67M | -57.7% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $46.55M | -48.7% | 2024-02-08, Balance as of period end |
| 2021-12-31 | $90.71M | -30.6% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $130.67M | n/m | 2022-02-24, Balance as of period end |
| 2019-12-31 | -$33.91M | n/m | 2022-02-24, Balance as of period end |
| 2018-12-31 | -$4.50M | n/m | 2020-03-19, Balance as of period end |
| 2017-12-31 | $23.99M | -18.0% | 2019-03-26, Balance as of period end |
| 2016-12-31 | $29.27M | -54.6% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $64.51M | +116.6% | 2018-03-08, Balance as of period end |
| 2014-12-31 | $29.78M | -34.1% | 2017-03-09, Balance as of period end |
| 2013-12-31 | $45.17M | +31.8% | 2016-02-29, Balance as of period end |
| 2012-12-31 | $34.27M | -14.1% | 2015-02-24, Balance as of period end |
| 2011-12-31 | $39.88M | -12.4% | 2014-03-13, Balance as of period end |
| 2010-12-31 | $45.52M | +37.7% | 2013-03-13, Balance as of period end |
| 2009-12-31 | $33.05M | n/a | 2012-02-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Curis Inc (CRIS) | 2025-12-31 | $5.46M | n/m |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $246.94M | +245.2% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $62.53M | +59.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $123.12M | -48.9% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $122.17M | -51.7% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $207.18M | -35.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $43.35M | -43.7% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $567.06M | -27.1% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $168.77M | +516.2% |
Compare CRIS, TSHA, ACOG, TCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗